NasdaqGS:TLRY

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. More Details


Snowflake Analysis

Slightly overvalued with limited growth.


Similar Companies

Share Price & News

How has Tilray's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TLRY's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

15.7%

TLRY

-2.3%

US Pharmaceuticals

-1.4%

US Market


1 Year Return

-73.6%

TLRY

9.2%

US Pharmaceuticals

17.8%

US Market

Return vs Industry: TLRY underperformed the US Pharmaceuticals industry which returned 10.9% over the past year.

Return vs Market: TLRY underperformed the US Market which returned 18.5% over the past year.


Shareholder returns

TLRYIndustryMarket
7 Day15.7%-2.3%-1.4%
30 Day20.1%-1.0%4.7%
90 Day-9.5%-1.8%8.2%
1 Year-73.6%-73.6%12.1%9.2%20.5%17.8%
3 Yearn/a21.4%12.4%42.2%32.7%
5 Yearn/a35.1%19.2%83.4%62.7%

Price Volatility Vs. Market

How volatile is Tilray's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Tilray undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: TLRY ($6.45) is trading below our estimate of fair value ($33.33)

Significantly Below Fair Value: TLRY is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: TLRY is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: TLRY is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TLRY's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TLRY is overvalued based on its PB Ratio (6.2x) compared to the US Pharmaceuticals industry average (3.1x).


Next Steps

Future Growth

How is Tilray forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?

71.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TLRY is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TLRY is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TLRY is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TLRY's revenue (32.2% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: TLRY's revenue (32.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if TLRY's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Tilray performed over the past 5 years?

-98.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TLRY is currently unprofitable.

Growing Profit Margin: TLRY is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TLRY is unprofitable, and losses have increased over the past 5 years at a rate of 98.3% per year.

Accelerating Growth: Unable to compare TLRY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TLRY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.6%).


Return on Equity

High ROE: TLRY has a negative Return on Equity (-396.47%), as it is currently unprofitable.


Next Steps

Financial Health

How is Tilray's financial position?


Financial Position Analysis

Short Term Liabilities: TLRY's short term assets ($289.8M) exceed its short term liabilities ($163.7M).

Long Term Liabilities: TLRY's short term assets ($289.8M) do not cover its long term liabilities ($560.6M).


Debt to Equity History and Analysis

Debt Level: TLRY's debt to equity ratio (366.1%) is considered high.

Reducing Debt: Insufficient data to determine if TLRY's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TLRY has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if TLRY has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Tilray current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TLRY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TLRY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TLRY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TLRY's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TLRY's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average management tenure


CEO

Brendan Kennedy (48 yo)

2.75yrs

Tenure

US$3,480,910

Compensation

Mr. Brendan Kennedy serves as Chief Executive Officer and Director of Tilray, Inc. since January 2018 and serves as its Chairman of the Board and as its President since January 2018. He serves as the Chief ...


CEO Compensation Analysis

Compensation vs Market: Brendan's total compensation ($USD3.48M) is about average for companies of similar size in the US market ($USD2.85M).

Compensation vs Earnings: Brendan's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Brendan Kennedy
Chairman2.75yrsUS$3.48m7.32%
$ 70.3m
Andrew Pucher
Chief Corporate Development Officer1.58yrsUS$4.54m0.016%
$ 149.6k
Kathryn Dickson
President of Manitoba Harvest USA0.83yrUS$130.23kno data
Michael Kruteck
Chief Financial Officer0.58yrno datano data
Jon Levin
Chief Operating Officer0.75yrno datano data
Dara Redler
General Counsel & Corporate Secretary1.75yrsno datano data
Rita Seguin
Chief Human Resources Officer1.75yrsno datano data
Greg Christopher
Executive Vice President of Operations0.75yrno datano data
Sascha Mielcarek
Managing Director of Europe1.67yrsno datano data
Josh Eades
Chief Science Officerno datano datano data
John Andonoff
Senior Vice President of Global Medical Sales Developmentno datano datano data
Kristina Adamski
Executive Vice President of Corporate Affairs1.33yrsno datano data

1.5yrs

Average Tenure

51yo

Average Age

Experienced Management: TLRY's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Brendan Kennedy
Chairman2.75yrsUS$3.48m7.32%
$ 70.3m
Howard Dean
Member of International Advisory Board1.83yrsno datano data
Lloyd Axworthy
Member of International Advisory Board1.83yrsno datano data
Praveen Anand
Member of Medical Advisory Boardno datano datano data
Michael Steele
Member of International Advisory Board1.83yrsno datano data
Catherine Lord
Member of Medical Advisory Boardno datano datano data
Christine St. Clare
Independent Director2.33yrsUS$378.73k0.015%
$ 148.6k
Abraham Chachoua
Member of Medical Advisory Boardno datano datano data
Michael Auerbach
Non-Independent Director2.67yrsUS$389.97k1.3%
$ 12.5m
Rebekah Dopp
Independent Director2.42yrsUS$371.77k0.016%
$ 149.0k
Orrin Devinsky
Chairman of Medical Advisory Boardno datano datano data
Elizabeth Hale
Member of Medical Advisory Boardno datano datano data

2.1yrs

Average Tenure

62.5yo

Average Age

Experienced Board: TLRY's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: TLRY insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 51.2%.


Top Shareholders

Company Information

Tilray, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Tilray, Inc.
  • Ticker: TLRY
  • Exchange: NasdaqGS
  • Founded: 2018
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$960.214m
  • Shares outstanding: 148.99m
  • Website: https://www.tilray.com

Number of Employees


Location

  • Tilray, Inc.
  • 1100 Maughan Road
  • Nanaimo
  • British Columbia
  • V9X IJ2
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TLRYNasdaqGS (Nasdaq Global Select)YesClass 2 Common StockUSUSDJul 2018
2HQDB (Deutsche Boerse AG)YesClass 2 Common StockDEEURJul 2018
2HQSWX (SIX Swiss Exchange)YesClass 2 Common StockCHCHFJul 2018
0Z6YLSE (London Stock Exchange)YesClass 2 Common StockGBUSDJul 2018
2HQXTRA (XETRA Trading Platform)YesClass 2 Common StockDEEURJul 2018

Biography

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products to patients, physicians, pharmacies, governments, and hospitals; and for ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/22 00:05
End of Day Share Price2020/10/21 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.